Srdan Verstovsek, MD, PhD | Authors

November 24, 2021

Circumstances for which hydroxyurea, ruxolitinib, or other therapy may be selected to treat newly diagnosed myelofibrosis.

November 15, 2021

Characteristics that contribute to treatment decisions for patients with newly diagnosed myelofibrosis

November 15, 2021

Criteria used to risk stratify and classify patients with newly diagnosed myelofibrosis and establish treatment paradigms.

November 11, 2021

The most common symptoms that present in patients with newly diagnosed myelofibrosis and variables that factor into initial treatment decisions.

November 11, 2021

The role of signaling pathways, mutations, and alterations in the development of myelofibrosis (MF), and characteristics that distinguish primary MF from secondary MF.

February 24, 2017

In this interview we discuss clinical developments in essential thrombocythemia, polycythemia vera, and myelofibrosis, as well as the latest treatment options.

June 01, 2016

Myeloproliferative neoplasms are a group of clonal myeloid cell–derived disorders characterized by myeloproliferation without dysplasia, bone marrow hypercellularity, and predisposition to thrombosis, hemorrhage, and bone marrow fibrosis.

July 15, 2013

By inhibiting inflammatory cytokines and controlling the signs and symptoms of myelofibrosis, the patient’s body condition improves as the disease is kept under good control. Ultimately, prolonged exposure of a patient with myelofibrosis to ruxolitinib at a clinically effective dose results in prolongation of the his or her life.

June 01, 2000

T-cell non-Hodgkin’s lymphomas are a heterogeneous group of diseases that differ markedly in terms of their clinical behavior and prognosis. In recently developed classification systems, the sites of initial disease